,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Dr. Frank Isaac Litvack FACC, M.D.', 'age': 66, 'title': 'Exec. Chairman', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 120000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
1,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Dr. Linda  Marb√°n Ph.D.', 'age': 59, 'title': 'Co-Founder, Pres, CEO & Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 282300, 'exercisedValue': 0, 'unexercisedValue': 1021739}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
2,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Mr. Anthony J. Bergmann M.B.A.', 'age': 36, 'title': 'CFO & Corp. Treasurer', 'yearBorn': 1986, 'fiscalYear': 2022, 'totalPay': 459150, 'exercisedValue': 0, 'unexercisedValue': 312174}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
3,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Ms. Karen G. Krasney', 'age': 69, 'title': 'Exec. VP, Gen. Counsel & Sec.', 'yearBorn': 1953, 'fiscalYear': 2022, 'totalPay': 434532, 'exercisedValue': 0, 'unexercisedValue': 267464}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
4,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Dr. Eduardo  Marb√°n', 'title': 'Co-Founder & Chairman of Scientific Advisory Board', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
5,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Dr. Kristi A. H. Elliott Ph.D.', 'title': 'Chief Science Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
6,10865 Road to the Cure,Suite 150,San Diego,CA,92121,United States,858 727 1755,https://www.capricor.com,Biotechnology,Healthcare,"Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome platform technology which generated two vaccine candidates, such as STX-S and STX-N, induced an immune response against two SARS-CoV-2 proteins, spike, and nucleocapsid, as well as developing vaccines and therapeutics for infectious and monogenic diseases, and other potential indications. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.",74,"{'maxAge': 1, 'name': 'Catherine Lee Kelleher', 'title': 'Consultant', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.525,6.5,6.245,6.67,6.525,6.5,6.245,6.67,0.0,3.897994,104.333336,225111,225111,126427,124420,124420,6.3,6.79,2900,1000,161363392,3.3,8.22,17.065321,5.7042,4.63835,0.0,0.0,USD,125795328,0.0,25228593,25776900,401446,276722,1690761600,1693440000,0.0156,0.02764,0.09689,1.95,0.016,0.106,59.056606,1672444800,1703980800,1688083200,-29226872,-1.13,0.06,1:10,1559692800,13.304,-4.241,NCM,EQUITY,CAPR,CAPR,"Capricor Therapeutics, Inc.","Capricor Therapeutics, Inc.",1171377000,America/New_York,EDT,-14400000,6.26,1.7,buy,37793456,1.466,-29662628,2225598,1.091,1.107,9455632,81.489,0.378,-0.36603,-2.72383,1746380,360502,-17795322,-1.98394,0.0,-3.22306,USD,
